Please use this identifier to cite or link to this item: https://doi.org/10.1101/gr.154492.113
Title: Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Authors: Kan, Z.
Zheng, H.
Liu, X.
Li, S.
Barber, T.D.
Gong, Z.
Gao, H.
Hao, K.
Willard, M.D.
Xu, J.
Hauptschein, R.
Rejto, P.A.
Fernandez, J.
Wang, G.
Zhang, Q.
Wang, B.
Chen, R.
Wang, J.
Lee, N.P.
Zhou, W.
Lin, Z.
Peng, Z.
Yi, K.
Chen, S.
Li, L.
Fan, X.
Yang, J.
Ye, R.
Ju, J.
Wang, K.
Estrella, H.
Deng, S.
Wei, P.
Qiu, M.
Wulur, I.H.
Liu, J.
Ehsani, M.E.
Zhang, C.
Loboda, A.
Sung, W.K. 
Aggarwal, A.
Poon, R.T.
Fan, S.T.
Wang, J.
Hardwick, J.
Reinhard, C.
Dai, H.
Li, Y.
Luk, J.M.
Mao, M.
Issue Date: Sep-2013
Citation: Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T.D., Gong, Z., Gao, H., Hao, K., Willard, M.D., Xu, J., Hauptschein, R., Rejto, P.A., Fernandez, J., Wang, G., Zhang, Q., Wang, B., Chen, R., Wang, J., Lee, N.P., Zhou, W., Lin, Z., Peng, Z., Yi, K., Chen, S., Li, L., Fan, X., Yang, J., Ye, R., Ju, J., Wang, K., Estrella, H., Deng, S., Wei, P., Qiu, M., Wulur, I.H., Liu, J., Ehsani, M.E., Zhang, C., Loboda, A., Sung, W.K., Aggarwal, A., Poon, R.T., Fan, S.T., Wang, J., Hardwick, J., Reinhard, C., Dai, H., Li, Y., Luk, J.M., Mao, M. (2013-09). Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research 23 (9) : 1422-1433. ScholarBank@NUS Repository. https://doi.org/10.1101/gr.154492.113
Abstract: Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). TheWnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 ( JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease. © 2013, Published by Cold Spring Harbor Laboratory Press.
Source Title: Genome Research
URI: http://scholarbank.nus.edu.sg/handle/10635/77946
ISSN: 10889051
DOI: 10.1101/gr.154492.113
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.